elobixibat Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5277 439087-18-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • elobixibat
  • elobixibat hydrate
  • A3309
  • AZD7806
  • AJG533
  • goofice
Elobixibat is an IBAT inhibitor approved in Japan for the treatment of chronic constipation. IBAT is the bile acid/sodium symporter responsible for the reuptake of bile acids in the ileum which is the initial step in the enterohepatic circulation. By inhibiting the uptake of bile acids, elobixibat increases the bile acid concentration in the gut, and this accelerates intestinal passage and softens the stool.
  • Molecular weight: 695.89
  • Formula: C36H45N3O7S2
  • CLOGP: 7.46
  • LIPINSKI: 2
  • HAC: 10
  • HDO: 3
  • TPSA: 142.11
  • ALOGS: -6.37
  • ROTB: 16

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Jan. 19, 2018 PMDA EA Pharma

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

None

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Chronic constipation indication 236069009

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.63 acidic
pKa2 12.17 acidic
pKa3 5.36 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Ileal sodium/bile acid cotransporter Transporter INHIBITOR IC50 9.28 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

IDSource
865UEK4EJC UNII
9414 INN_ID
9939892 PUBCHEM_CID
D10795 KEGG_DRUG
9996 IUPHAR_LIGAND_ID
DB12486 DRUGBANK_ID
CHEMBL3039515 ChEMBL_ID
C581303 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

None